{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:15:48Z","timestamp":1761844548089,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:00:00Z","timestamp":1438300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Chugai Pharmaceutical Co Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.cllc.2015.07.001","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:59:32Z","timestamp":1438217972000},"page":"24-29.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1016","volume":"17","author":[{"given":"Makoto","family":"Nishio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Chikamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Katakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-8370","authenticated-orcid":false,"given":"Norihisa","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2015.07.001_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non\u2013small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2015.07.001_bib2","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e31818d6702","article-title":"Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non\u2013small-cell lung cancer: a phase II study","volume":"3","author":"Kubota","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.07.001_bib3","first-page":"557","article-title":"Phase II study of erlotinib in Japanese patients with advanced non\u2013small-cell lung cancer","volume":"30","author":"Takahashi","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2015.07.001_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation\u2013positive non\u2013small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2015.07.001_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","article-title":"A\u00a0prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation\u2013positive advanced non\u2013small-cell lung cancer","volume":"82","author":"Goto","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2015.07.001_bib6","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/nar\/17.7.2503","article-title":"Analysis of any point mutation in DNA. The amplification refractory system (ARMS)","volume":"17","author":"Newton","year":"1989","journal-title":"Nucleic Acid Res"},{"key":"10.1016\/j.cllc.2015.07.001_bib7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/11751","article-title":"Detection of PCR products using self-probing amplicons and fluorescence","volume":"17","author":"Whitcombe","year":"1999","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cllc.2015.07.001_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/sj.bjc.6603949","article-title":"Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)","volume":"97","author":"Kimura","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2015.07.001_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/JTO.0b013e3182307f98","article-title":"Epidermal growth factor receptor mutation status in circulating free DNA in serum","volume":"7","author":"Goto","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.07.001_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JTO.0b013e3181fb7cf1","article-title":"Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion","volume":"6","author":"Laack","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.07.001_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2011.12.017","article-title":"Metastatic brain tumors from non\u2013small-cell lung cancer with deletion on radiographic features","volume":"77","author":"Sekine","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2015.07.001_bib12","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2008.17.3930","article-title":"Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non\u2013small-cell lung cancer","volume":"27","author":"Bai","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.07.001_bib13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2015.07.001_bib14","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2015.07.001_bib15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730415001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730415001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:04:55Z","timestamp":1761505495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730415001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1525730415001813"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2015.07.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non\u2013Small-Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2015.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}